米力农联合心通口服液治疗慢性充血性心衰的临床疗效

发布时间：2018-03-14 07:06

本文选题：米力农　切入点：心通口服液　出处：《河北大学》2016年硕士论文　论文类型：学位论文

【摘要】：目的观察米力农联合心通口服液治疗慢性心力衰竭的临床疗效以及对患者生活质量影响。方法将92例慢性充血性心力衰竭患者随机分成两组,其中联合用药组46人,对照组46人。所有患者均采取使用利尿剂、口服血管紧张素转换酶抑制药等常规治疗,联合用药组患者在常规治疗基础上采用米力农联合心通口服液治疗,对照组患者在常规治疗基础上单独应用米力农治疗。从临床疗效、血浆N末端B型利钠肽(NT-proBNP),左心室舒张末期内径值及左心室射血分数指标进行评价,同时还监测患者的肝功能和肾功能变化。结果联合用药组临床疗效总有效率明显的高于米力农组,两组比较差异有统计学意义(63%VS.82.6%,P0.05)。经过两个疗程(6周)治疗后与治疗前比较,联合用药组和米力农组左心室射血分数(LVEF)水平均明显增加,差异具有统计学意义(P0.05);联合用药组较米力农组LVEF升高更明显,两组间比较差异有统计学意义(P0.05)。经过两个疗程(6周)治疗后,联合用药组和米力农组血浆N末端B型利钠肽(NT-pro BNP)明显下降,差异具有统计学意义(P0.05);联合用药组较米力农组血浆NT-BNP下降更明显,两组间比较有统计学意义(P0.05)。联合用药组及米力农组左心室舒张末期内径(LVD)治疗前后未见明显的变化。联合用药组及米力农组肝功能、肾功能指标在治疗前与治疗后未见明显的变化。结论米力农注射液在加用心通口服液治疗CHF的临床效果明显的好于单独的应用米力农治疗CHF。
[Abstract]:Objective to observe the clinical effect of milrinone combined with Xintong oral liquid on the quality of life of patients with chronic heart failure. Methods 92 patients with chronic congestive heart failure were randomly divided into two groups, including 46 patients in combination group. 46 patients in the control group were treated with diuretic, oral angiotensin converting enzyme inhibitor and other routine therapy. The patients in the combined treatment group were treated with milrinone combined with Xintong oral liquid on the basis of routine treatment. The control group was treated with milrinone alone on the basis of routine therapy. The clinical efficacy, plasma N-terminal B-type natriuretic peptide NT-proBNPN, left ventricular end-diastolic diameter and left ventricular ejection fraction (LVEF) were evaluated. Results the total effective rate of the combined treatment group was significantly higher than that of the milrinone group, and the difference between the two groups was statistically significant (P 0.05). After two courses of treatment (6 weeks), the total effective rate was compared with that before treatment. The level of left ventricular ejection fraction (LVEF) in combination group and milrinone group was significantly increased, the difference was statistically significant (P 0.05), and the level of LVEF in combination group was significantly higher than that in milrinone group. The difference between the two groups was statistically significant (P 0.05). After two courses of treatment (6 weeks), the plasma N-terminal natriuretic peptide N-terminal type B natriuretic peptide (NT-pro BNPs) in the combined treatment group and milrinone group decreased significantly. The difference was statistically significant (P 0.05), the plasma NT-BNP in combination group was significantly lower than that in milrinone group. There was no significant change in left ventricular end-diastolic diameter before and after treatment in combination group and milrinone group. Liver function was observed in combination group and milrinone group. Conclusion the clinical effect of milrinone injection in the treatment of CHF is better than that in the single application of milrinone in the treatment of CHF.
【学位授予单位】：河北大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R541.61

【相似文献】